Skip to content

COVID-19 Information & Videos »
Find a Doctor »
Zip Code

x

For Patients
For Physicians
Neuronetics

For Patients
For Physicians
Neuronetics

Why NeuroStar
About NeuroStar
Patient Corner
Insurance

Precision Matters
The Precise Choice
Efficacy and Results
Insurance
Be a TMS Leader

Solutions
Investors
Meet the Team
News
Careers

Contact Us
Global Sites
- English
- Deutsch
- 日本語
- 한국어

How it Works
Is it Right for You?
Clinical Results

Coding and Billing
Medical Coverage Policies
Health Insurance Coverage
Services
Resources

Neuronetics Board

Safety & Tolerability
Precision
About Depression

Overview
Stock Information
News & Events
Financial Information
Corporate Governance
Investor Resources

The Key Role in TMS
TMS Myth vs Fact

Unique Coil
TrakStar
MT Assist
Safety
Practice Setting
Qualified Candidates

Practice Support
Practice Success Program
Clinical Training
Field Services
Patient Education
Public Relations
Providers
Events and Exhibits

Outcomes Registry
Mechanism of Action
Physician & Patient Testimonials
Scientific Publications

Non-Drug NeuroStar TMS Therapy Shows Favorable Outcomes Compared to Oral Anti- Depressants in Treating Major Depressive Disorder

Post navigation

NeuroStar TMS Therapy Shows Promise as Effective Once-Monthly Maintenance Therapy in Patients with Major Depressive Disorder

Data Published Online in The Journal of Clinical Psychiatry Show Long-Term Benefit of Non-Drug NeuroStar TMS Therapy® in Patients with Treatment Resistant Depression

Leave a Reply Cancel reply

You must be logged in to post a comment.

Indication

NeuroStar TMS Therapy is indicated for the treatment of Major Depressive Disorder in adult patients who have failed to receive satisfactory improvement from prior antidepressant medication in the current episode.

NeuroStar TMS Therapy is only available by prescription. A doctor can help decide if NeuroStar TMS Therapy is right for you. Patients’ results may vary.

Important Safety Information

The most common side effect is pain or discomfort at or near the treatment site. These events are transient; they occur during the TMS treatment course and do not occur for most patients after the first week of treatment. There is a rare risk of seizure associated with the use of NeuroStar TMS (<0.1% per patient).

NeuroStar TMS Therapy should not be used with patients who have non-removable conductive metal in or near the head. NeuroStar TMS Therapy has not been studied in patients who have not received prior antidepressant treatment.
Safety and Prescribing Information »

Our Commitment

Neuronetics is committed to compliance with state and federal laws regarding interaction with healthcare providers.
Commitment to Compliance »

Patient Resources
NeuroStar TMS
International
- English
- Deutsch
- 日本語
- 한국어
Website
Contact Us
- 1-877-600-7555
- Facebook
- Twitter
- Instagram
- YouTube
- LinkedIn

Copyright @ 2021 Neuronetics. All Rights Reserved.